Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly (NYSE:LLY) announced Thursday that its diabetes therapy, Mounjaro (tirzepatide), succeeded in a late-stage trial ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Treatment with a once-weekly dose of 0.75 mg or 1.5 mg dulaglutide was better than placebo in improving glycemic control among youths with type 2 diabetes (T2D).

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

Participants were randomized to receive mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks. The primary endpoint was the change in HbA1c from baseline to week 28.

For instance, one 2023 study found that giving dulaglutide to rats with vascular dementia, a common form of dementia caused by decreased blood flow to the brain, appeared to alleviate brain tissue ...

Adobe Stock ESRD or an eGFR reduction of at least 40% occurred in 5.2% of those taking 1.5 mg dulaglutide, 8.4% of those taking 0.75 mg dulaglutide and 10.8% of those taking insulin glargine.